1990-2015年全球及区域神经系统疾病负担:GBD 2015系统分析
该研究基于GBD 2015系统分析,量化了2015年全球神经系统疾病负担及其与国家发展水平的关系。
要点
- 紧张型头痛和偏头痛是最常见的神经系统疾病。
- 低SDI国家以传染性神经系统疾病为DALYs主因。
核心结论
- 神经系统疾病是全球致残和致死的重要原因,过去25年负担因人口增长和老龄化而大幅增加。
- 尽管卒中与传染性神经系统疾病的死亡率显著下降,需神经科专业照护的患者数未来数十年将持续增长。
研究设计与样本
- 系统分析基于GBD 2015,估计全球及国家特异性患病率、死亡率、DALYs、YLLs和YLDs。
- 纳入卒中、脑膜炎、脑炎、破伤风、阿尔茨海默病及其他痴呆、帕金森病、癫痫、多发性硬化、运动神经元病、偏头痛、紧张型头痛、药物过度使用性头痛、脑与神经系统癌症及其他神经系统疾病残余类。
- 按社会人口指数(SDI)分析结果,SDI为人均收入、教育和生育率的复合指标。
主要发现
- 传染性神经系统疾病是低SDI国家DALYs的最大原因;卒中率在中等SDI最高、最高SDI最低。
临床怎么用
- 应认识到神经系统疾病负担持续增长,需为神经科专业照护需求增加做好准备。
- 政策制定者和医疗服务提供者应关注上述趋势,以提供充足服务。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comparable data on the global and country-specific burden of neurological disorders and their trends are crucial for health-care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study provides such information but does not routinely aggregate results that are of interest to clinicians specialising in neurological conditions. In this systematic analysis, we quantified the global disease burden due to neurological disorders in 2015 and its relationship with country development level. METHODS: We estimated global and country-specific prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) for various neurological disorders that in the GBD classification have been previously spread across multiple disease groupings. The more inclusive grouping of neurological disorders included stroke, meningitis, encephalitis, tetanus, Alzheimer's disease and other dementias, Parkinson's disease, epilepsy, multiple sclerosis, motor neuron disease, migraine, tension-type headache, medication overuse headache, brain and nervous system cancers, and a residual category of other neurological disorders. We also analysed results based on the Socio-demographic Index (SDI), a compound measure of income per capita, education, and fertility, to identify patterns associated with development and how countries fare against expected outcomes relative to their level of development. FINDINGS: Neurological disorders ranked as the leading cause group of DALYs in 2015 (250·7 [95% uncertainty interval (UI) 229·1 to 274·7] million, comprising 10·2% of global DALYs) and the second-leading cause group of deaths (9·4 [9·1 to 9·7] million], comprising 16·8% of global deaths). The most prevalent neurological disorders were tension-type headache (1505·9 [UI 1337·3 to 1681·6 million cases]), migraine (958·8 [872·1 to 1055·6] million), medication overuse headache (58·5 [50·8 to 67·4 million]), and Alzheimer's disease and other dementias (46·0 [40·2 to 52·7 million]). Between 1990 and 2015, the number of deaths from neurological disorders increased by 36·7%, and the number of DALYs by 7·4%. These increases occurred despite decreases in age-standardised rates of death and DALYs of 26·1% and 29·7%, respectively; stroke and communicable neurological disorders were responsible for most of these decreases. Communicable neurological disorders were the largest cause of DALYs in countries with low SDI. Stroke rates were highest at middle levels of SDI and lowest at the highest SDI. Most of the changes in DALY rates of neurological disorders with development were driven by changes in YLLs. INTERPRETATION: Neurological disorders are an important cause of disability and death worldwide. Globally, the burden of neurological disorders has increased substantially over the past 25 years because of expanding population numbers and ageing, despite substantial decreases in mortality rates from stroke and communicable neurological disorders. The number of patients who will need care by clinicians with expertise in neurological conditions will continue to grow in coming decades. Policy makers and health-care providers should be aware of these trends to provide adequate services. FUNDING: Bill & Melinda Gates Foundation.
引用
- Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017. PMID: 28931491. doi:10.1016/S1474-4422(17)30299-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。